A promising cancer treatment is poised for explosive growth, says Redburn Atlantic. These stocks are on its buy list

  • 📰 CNBC
  • ⏱ Reading Time:
  • 46 sec. here
  • 17 min. at publisher
  • 📊 Quality Score:
  • News: 74%
  • Publisher: 72%

Prostate Cancer ニュース

Cancer,Radiation Therapy,Biotech And Pharmaceuticals

Redburn Atlantic named the stocks it believes will benefit from the increased opportunities in radiopharmaceuticals.

The latest weapon in the battle against cancer is showing promising results — and it's a growing opportunity for investors, according to Redburn Atlantic. Radiopharmaceuticals are used to detect and treat the disease. They have also helped provided more accurate diagnoses and a way to attack tumors without damaging healthy cells. Big pharma is betting billions on the treatments, with a number of acquisitions in the space in recent years.

mountain GE Healthcare's one-year performance "We expect the company to be able to deliver strong improvements in profitability, supported by operational leverage, improving mix — led by accelerating growth in radiopharmaceuticals — and an extensive efficiency programme," he wrote. Meanwhile, Ridley-Day initiated coverage last week on Lantheus with a buy rating and $175 price target, suggesting nearly 72% upside from Wednesday's close.

mountain Lantheus Holding's one-year performance The company is a leading supplier of radiopharma diagnostic agents and is also moving into radiopharma therapeutics. It has a "strong pipeline of radionuclides for both diagnosis and therapy," he said. "Lantheus benefits from its focus on this rapidly expanding market, with 78% of revenues from radiopharmaceuticals and related products," Ridley-Day added.

 

コメントありがとうございます。コメントは審査後に公開されます。
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 12. in JP

日本 最新ニュース, 日本 見出し